Pfizer research chief just detailed on earnings call what sounds like an interesting divergence in #covid19 vaccine strategy re: variants compared with Moderna. Says Pfizer testing boosts of original vaccine at 6 and 12 months out. (1)
Pfizer's Dolsten notes mRNA vaccines generate high antibody levels, and expects even against B.1.351 & P1 variants that those levels mean the vaccines will be "much more resistant to breakthroughs."
Expects a booster w original vaccine may get antibody levels high enough. (2)
Expects a booster w original vaccine may get antibody levels high enough. (2)
In contrast, Moderna has said it's already working on a new #covid19 vaccine construct, mRNA-1273.351, in case it's needed: investors.modernatx.com/news-releases/…
Moderna also testing booster w original (3)
Moderna also testing booster w original (3)
Pfizer isn't ruling out needing to create new #covid19 vaccine constructs and notes it has flexibility w mRNA platform to move quickly if needed, but tone is certainly more confident that a booster should provide needed protection, vs needing a new construct soon. (4)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
